-
1 Comment
Hyloris Pharmaceuticals SA is currently in a long term uptrend where the price is trading 15.3% above its 200 day moving average.
From a valuation standpoint, the stock is 96.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 2541.1.
Based on the above factors, Hyloris Pharmaceuticals SA gets an overall score of 2/5.
| Industry | Biotechnology |
|---|---|
| Sector | Healthcare |
| ISIN | BE0974363955 |
| CurrencyCode | EUR |
| Exchange | BR |
| Beta | 0.72 |
|---|---|
| Market Cap | 369M |
| Dividend Yield | 0.0% |
| Target Price | 19.7 |
| PE Ratio | None |
Hyloris Pharmaceuticals SA engages in the develop, manufacture, and deliver pharmaceutical products to address unmet medical needs in cardiovascular health and other major therapeutic areas. It offers cardiovascular products for atrial fibrillation, acute coronary syndrome, advanced heart failure, congestive heart failure, acute coronary syndrome, and coronary heart disease. The company provides Maxigesic IV, a combination of paracetamol and ibuprofen used for post-operative non-opioid pain management; Tranexamic acid RTU, an antifibrinolytic drug for the formation of blood clots; Miconazole/Domiphen Bromide, a topical synergistic combination treatment for Recurrent Vulvovaginal Candidiasis; AlenuraTM, a first-line drug treatment for acute pain in interstitial cystitis/bladder pain syndrome; and Plecoid Agent IV for the treatment of acute myeloid leukemia and small cell lung cancer. It also offers Atomoxetine, an oral liquid for the treatment of patients with attention deficit hyperactivity disorder; HY-029, a liquid formulation of an antiviral drug to treat viral infections; HY-083, a nasal spray for the treatment of idiopathic rhinitis; and HY-088, an oral liquid that treats hypophosphatemia. The company was incorporated in 2012 and is headquartered in Liège, Belgium.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for HYL.BR using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2024
